Author: Carlos

Cagrilintide, CagriSema, petrelintide and eloralintide – the reported weight-loss numbers, durations and caveats, including the REDEFINE 4 head-to-head miss.

Predicting peptide solubility means reading the sequence: which residues carry charge, what the net charge is at your diluent pH, and how much of the powder is peptide at all.

Peptide-drug conjugates promise antibody-style targeting at a fraction of the size. Here is how the three-module design works, why the linker matters more than the peptide, and what the regulatory record actually shows.

BNP and NT-proBNP come from the same prohormone but behave differently. What each marker measures, what else moves the number, and why one drug splits them apart.

Parathyroid hormone removes bone when it stays switched on and adds bone when it arrives as a daily spike. Here is why the exposure curve, not the dose, decides.

Irisin is a myokine released by working muscle that browns white fat in mice. What is verified, why reported blood levels span six orders of magnitude, and what human data actually show.

Dietary proteins hide short bioactive food peptides that only become active once an enzyme cuts them free – here is what the trials and regulators actually concluded.

Chemokines are the small signalling proteins that direct immune-cell traffic – how the CC, CXC, CX3C and XC families work, and why so few drugs against them succeed.

How peptide vaccines train T cells, why long peptides and adjuvants are required, where neoantigen cancer trials really stand, and why none is FDA approved.

Apelin dilates arteries, boosts cardiac output and opposes both angiotensin II and vasopressin — yet after nearly thirty years it has produced no approved drug. What the peptide is, what ELABELA changed, and why the pathway is hard.